Searched for
AGILA SPECIALTIES PHARMA CORPORATION
India Inc profit hit from West Asia tensions to halve if truce holds, Crisil saysCorporate India's profitability impact from the West Asia conflict is now expected to be half of initial fears, with Crisil Ratings predict...- Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
- Centre set to tighten oversight of pharma packaging materialsIndia is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This mov...
- Strong balance sheets help India Inc absorb West Asia fallout: CrisilA stress test by Crisil Ratings covering 34 sectors that account for 65% of its rated corporate debt suggests that India Inc remains broadl...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- Broader market winners! How investors found 15 multibaggers in a muted Nifty year?Despite a subdued Nifty, several Indian stocks have surged, becoming multibaggers for investors. This outperformance is attributed to resil...
- RICE Adamas Group expands national footprint with Mumbai Office inaugurationAdamas University and Adamas Tech Consulting have launched a new Mumbai office and the Adamas School of Experiential Learning, offering 10-...
- Capex boom, global sourcing tailwinds fuel textile stock rallyTextile exporter stocks witnessed a significant rally on Wednesday, boosted by positive initiation of coverage from Motilal Oswal Financial...
- India's GIC Re plans to reduce share of overseas property risk as climate losses riseIndian reinsurer GIC Re is strategically shifting its overseas business focus. Amidst escalating climate-related losses globally, the compa...
- Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
- Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise valueMamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...
- Ahead of Market: 10 things that will decide stock market action on WednesdaySensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 24%When business updates start to come in or when some FMCG or auto companies indicate that things are not all good in the rural space, we may...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- Chennai Petroleum Corporation gets Navratna status, becomes 28th such CPSEChennai Petroleum Corporation Ltd (CPCL) has achieved Navratna status, a significant upgrade granting it greater financial and operational ...
- Novyte, Chemvera partner to create pathway for AI-driven material discoveryThis collaboration leverages Novyte's AI engine for materials discovery and Chemvera's manufacturing expertise, creating an end-to-end Indi...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
Load More
